PTCy、阿巴西普与短程他克莫司预防单倍体移植后GVHD
一项1b-2期临床试验评估PTCy、阿巴西普与短程他克莫司(CAST)联合方案在外周血单倍体造血干细胞移植后预防GVHD的安全性和疗效,主要终点为+120天内2-4级急性GVHD发生率。共纳入46例患者,中位年龄60岁,2-4级和3-4级急性GVHD累积发生率分别为17.4%和4.4%,毒性反应与单倍体移植预期相似。
要点
- CAST方案在外周血单倍体移植后2-4级急性GVHD累积发生率为17.4%(95%CI 9.2-32.9)。
- 3-4级急性GVHD累积发生率为4.4%(95%CI 1.1-17.1),1年治疗相关死亡率为4.4%(95%CI 1.1-17.1)。
- 毒性反应与接受单倍体移植患者的预期毒性相似。
核心结论
- CAST方案可安全有效地降低外周血单倍体造血干细胞移植后2-4级急性GVHD发生率。
研究设计与样本
- 1b-2期临床试验,评估PTCy、阿巴西普与短程他克莫司(CAST)联合方案在外周血单倍体造血干细胞移植后的应用,主要终点为+120天内2-4级急性GVHD发生率,共纳入46例患者,中位年龄60岁(范围18-74岁),试验注册号NCT04503616。
主要发现
- 2-4级急性GVHD累积发生率为17.4%(95%CI 9.2-32.9),3-4级急性GVHD累积发生率为4.4%(95%CI 1.1-17.1)。
- 中位随访15.3个月,1年治疗相关死亡累积发生率为4.4%(95%CI 1.1-17.1)。
- 估计1年中重度慢性GVHD发生率为15.9%(95%CI 8-31.7),复发率为11.7%(95%CI 5-27.2),无进展生存率为84.1%(95%CI 73.8-95.7),总生存率为85.9%(95%CI 75.9-97.2),无GVHD且无复发生存率为66.1%(95%CI 53.4-81.8)。
- 毒性反应与接受单倍体造血干细胞移植患者的预期毒性相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Reducing the incidence of graft-versus-host disease (GVHD) after haploidentical hematopoietic stem cell transplantation (HSCT) is warranted. Posttransplant cyclophosphamide (PTCy) is the main agent used for GVHD prevention in this setting. It remains unknown whether costimulation blockade can be safely combined with PTCy and enhance its efficacy. We performed a phase 1b-2 clinical trial to examine the combination of PTCy, abatacept, and a short course of tacrolimus (CAST) after peripheral blood haploidentical HSCT. The primary end point was the incidence of grades 2-4 acute GVHD by day +120. The study enrolled 46 patients with a median age of 60 years (range, 18-74 years). The cumulative incidences of grades 2-4 and 3 or 4 acute GVHD were 17.4% (95% confidence interval [CI], 9.2-32.9) and 4.4% (95% CI, 1.1-17.1), respectively. With a median follow-up of 15.3 months, the cumulative incidence of 1-year treatment-related mortality was 4.4% (95% CI, 1.1-17.1). The estimated 1-year moderate-to-severe chronic GVHD rate, relapse rate, progression-free survival, overall survival, and GVHD- and relapse-free survival were 15.9% (95% CI, 8-31.7), 11.7% (95% CI, 5-27.2), 84.1% (95% CI, 73.8-95.7), 85.9% (95% CI, 75.9-97.2), and 66.1% (95% CI, 53.4-81.8), respectively. Toxicities were similar to those expected in patients receiving haploidentical HSCT. This clinical trial showed that the CAST regimen is safe and effective in reducing the rate of grades 2-4 acute GVHD after haploidentical peripheral blood HSCT. This trial was registered at www.clinicaltrials.gov as #NCT04503616.
引用
- Al-Homsi AS, Cirrone F, Wo S, et al. PTCy, abatacept, and a short course of tacrolimus for GVHD prevention after haploidentical transplantation. Blood Adv. 2023. PMID: 37163349. doi:10.1182/bloodadvances.2023010545
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。